[1]王慧霞段玉红宋宗良张效科李嘉瑞 彭皞.中成药治疗糖尿病肾病的系统评价再评价[J].陕西中医药大学学报,2024,(05):014-23.[doi:10.13424/j.cnki.jsctcm.2024.05.003]
　WANG HuixiaDUAN Yuhong SONG Zongliang ZHANG Xiaoke LI Jiarui PENG Hao.Re Evaluation of Traditional Chinese Patent Medicines and Simple Preparations in the Treatment of Diabetes Nephropathy[J].Journal of Shaanxi University of Traditional Chinese Medicine,2024,(05):014-23.[doi:10.13424/j.cnki.jsctcm.2024.05.003]
点击复制

中成药治疗糖尿病肾病的系统评价再评价()
分享到：

《陕西中医药大学学报》[ISSN:2096-1340/CN:61-1501/R]

卷:
期数:
2024年05期
页码:
014-23
栏目:
出版日期:
2024-09-09

文章信息/Info

Title:
Re Evaluation of Traditional Chinese Patent Medicines and Simple Preparations in the Treatment of Diabetes Nephropathy
文章编号:
2096-1340(2024)05-0014-10
作者:
王慧霞1段玉红2宋宗良2张效科1李嘉瑞1 彭皞1
1.陕西中医药大学，陕西 咸阳 712046，
2.陕西中医药大学附属医院，陕西 咸阳 712000
Author(s):
WANG Huixia1DUAN Yuhong2 SONG Zongliang2 ZHANG Xiaoke1 LI Jiarui1 PENG Hao1
1.Shaanxi University of Chinese Medicine,Shaanxi Xianyang 712046,China;
2.Affiliated Hospital of Shaanxi University of Chinese Medicine,Shaanxi Xianyang 712000,China
关键词:
关键词：糖尿病肾病; 中成药; AMSTAR 2; PRISMA; 系统评价再评价
Keywords:
Key words： Diabetes nephropathy; Traditional Chinese patent medicines and simple preparations; AMSTAR 2; PRISMA; Systematic evaluation and re evaluation
分类号:
R587.1
DOI:
10.13424/j.cnki.jsctcm.2024.05.003
文献标志码:
A
摘要:
摘 要：目的 评价中成药治疗糖尿病肾病（diabetic kidney disease,DKD）系统评价（systematic reviews,SRs）的方法学质量和报告质量，评估中成药治疗糖尿病肾病的疗效及不良反应，以期为其临床应用提供循证医学证据。方法 检索PubMed、Cochrane Library、Embase、CBM、CNKI、VIP和Wanfang Data数据库，2名研究者独立筛选文献、提取资料，纳入中成药治疗DKD的SRs，采用AMSTAR 2（a measurement tool to assess systematic reviews-2）及PRISMA（reporting items for systematic reviews and meta-analysis）评价纳入SRs的方法学质量和报告质量，并用表格呈现Meta分析结果。结果 共纳入28篇SRs，AMSTAR2评价结果为：18篇SRs为中质量，7篇SRs为低质量，3篇SRs为极低质量；PRISMA评价结果为：20篇SRs报告相对完整，7篇SRs报告存在一定的缺陷，1篇SR报告存在严重缺陷；结论 现有证据显示，中成药治疗DKD在提高有效率、改善实验室指标及降低不良反应均优于常规西医治疗，但纳入SRs的方法学质量及报告质量存在一定缺陷，应慎重对待该结论。因此，为了更好的指导临床实践，未来相关SRs的方法学质量及报告质量需要进一步的提高。
Abstract:
Abstract： Objective To evaluate the methodological quality and reporting quality of systematic reviews (SRs) of traditional Chinese patent medicines and simple preparations in the treatment of diabetes nephropathy (DKD),evaluate the efficacy and adverse reactions of traditional Chinese patent medicines and simple preparations in the treatment of diabetes nephropathy,and provide evidence-based medical evidence for its clinical application.Methods The PubMed,Cochrane Library,Embase,CBM,CNKI,VIP and Wanfang Data databases were retrieved.Two researchers independently screened the literature,extracted the data,and included SRs of traditional Chinese patent medicines and simple preparations in the treatment of DKD.AMSTAR 2 (a measurement tool to assess systematic reviews-2) and PRISMA (reporting items for systematic reviews and meta analysis) were used to evaluate the methodological quality and reporting quality of SRs,and the Meta analysis results were presented in tables.Results A total of 28 SRs were included,and the AMSTAR2 evaluation results showed that 18 SRs were of medium quality,7 SRs were of low quality,and 3 SRs were of extremely low quality;The PRISMA evaluation results are: 20 SRs reports are relatively complete,7 SRs reports have certain defects,and 1 SRs report has serious defects.Conclusion The existing evidence shows that traditional Chinese patent medicines and simple preparations is superior to conventional western medicine in improving the effective rate,improving laboratory indicators and reducing adverse reactions in the treatment of DKD,but there are some defects in the methodological quality and reporting quality of SRs,which should be treated cautiously.Therefore,in order to better guide clinical practice,the methodological and reporting quality of relevant SRs need to be further improved in the future.

参考文献/References:

［1］中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏病防治指南（2021年版）［J］.中华糖尿病杂志,2021,13(8):762-784.
［2］RUIZ-ORTEGA M,RODRIGUES-DIEZ RR,LAVOZ C,et al.Special Issue “Diabetic Nephropathy:Diagnosis,Prevention and Treatment”［J］.J Clin Med,2020,9(3):813.
［3］HOU JH,ZHU HX,ZHOU ML,et al.Changes in the spectrum of kidney diseases:an analysis of 40,759 biopsy-proven cases from 2003 to 2014 in China［J］.Kidney Dis (Basel),2018,4(1):10-19.
［4］中华医学会肾脏病学分会专家组.糖尿病肾脏疾病临床诊疗中国指南［J］.中华肾脏病杂志,2021,37(3):255-304.
［5］杜丽沙,马鸿杰.中医药治疗糖尿病肾病研究状况及趋势的可视化分析［J］.湖南中医杂志，2021,37(12):129-134,142.
［6］高岩,宋宗良,段玉红,等.百令胶囊辅助治疗糖尿病肾病的Meta分析［J］.药物评价研究,2021,44(1):161-169.
［7］张婧,李靖,张海力,等.尿毒清颗粒联合血管紧张素系统阻滞剂治疗糖尿病肾病的Meta分析［J］.世界中医药,2021,16(2):274-283.
［8］龚丽,黄寅銮,谢韶妍,等.百令胶囊联合缬沙坦治疗糖尿病肾病临床疗效及安全性的Meta分析［J］.广州中医药大学学报,2021,38(5):1061-1066.
［9］魏远清,陈静.丹参注射液联合前列地尔治疗糖尿病肾病临床疗效及安全性Meta分析［J］.新中医,2020,52(16):16-20.
［10］黄玲珑,王冠东,张捷平,等.济生肾气丸用于糖尿病肾病临床疗效的系统评价［J］.中国医院用药评价与分析,2020,20(5):586-592.
［11］连心逸,柳红芳,王向明,等.金水宝胶囊联合血管紧张素转换酶抑制剂治疗糖尿病肾病系统评价［J］.中国中医药信息杂志,2020,27(9):103-107.
［12］张俊华,商洪才,张伯礼.系统评价和Meta分析质量的评价方法［J］.中西医结合学报,2008,6(4):337-340.
［13］葛龙,潘蓓,潘佳雪,等.解读AMSTAR-2——基于随机和(或)非随机对照试验系统评价的质量评价工具［J］.中国药物评价,2017,34(5):334-338.
［14］高亚,刘明,杨珂璐,等.系统评价报告规范：PRISMA 2020与PRISMA 2009的对比分析与实例解读［J］.中国循证医学杂志,2021,21(5):606-616.
［15］SHENG XH,YANG D,CHENG D S,et al.Efficacy and safety of Bailing capsules in the treatment of type 2 diabetic nephropathy:a meta-analysis［J］.Ann Palliat Med，2020，9(6):3885-3898.
［16］TAN YM,HU J,WU Q,et al.Fufang Xueshuantong for Diabetic Kidney Disease:A Systematic Review and Meta-Analysis［J］.Evidence-Based Complement Alternat Med，2020（12）:9326948.
［17］黄雅兰,黄国东,蔡林坤,等.百令胶囊联合RAAS阻断剂治疗早期糖尿病肾病疗效和安全性的系统评价［J］.中华中医药学刊,2019,37(6):1290-1297.
［18］甘文渊.肾炎康复片治疗糖尿病肾病的Meta分析及系统评价［J］.时珍国医国药,2018,29(4):1014-1016.
［19］QIANG L,LI CL,CHEN WW,et al.Clinical efficacy of Jin Shui Bao Capsules Combined with Angiotensin Receptor Blockers in Patients with Early Diabetic Nephropathy:A Meta-Analysis of Randomized Controlled Trials［J］.Evid Based Complement Alternat Med，2018:6806943.
［20］王荣,张莲,艾金伟,等.肾炎康复片联合西医常规疗法治疗糖尿病肾病有效性的Meta分析［J］.世界中医药,2017,12(1):180-185,190.
［21］黄秋明,孙洁雨.复方血栓通胶囊联合血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体拮抗剂治疗早期糖尿病肾病疗效的系统评价［J］.中国医院用药评价与分析,2016,16(8):1081-1087.
［22］许帅,邓小凤,冯秋苑,等.复方血栓通胶囊治疗糖尿病肾病Ⅲ期的系统评价［J］.辽宁中医杂志,2016,43(11):2249-2253.
［23］邓小凤,许帅,朱章志.参芪降糖颗粒治疗糖尿病肾病Ⅲ期的系统评价［J］.内蒙古中医药,2016,35(7):1-3.
［24］LAN L,WANG QH,YI YX,et al.Liuwei Dihuang Pills Enhance the Effect of Western Medicine in Treating Diabetic Nephropathy:A Meta-Analysis of Randomized Controlled Trials［J］.Evid Based Complement Alternat Med，2016:1509063.
［25］段蓉,李正翔.金水宝联合血管紧张素受体阻滞剂治疗糖尿病肾病的Meta分析［J］.药物评价研究,2015,38(1):78-84.
［26］王海焱,刘铜华.参芪降糖颗粒治疗糖尿病肾病Meta分析［J］.世界科学技术-中医药现代化,2015,17(12):2608-2613.
［27］刘丽,詹钊,韩冰冰.丹参注射液治疗糖尿病肾病的系统评价［J］.山西医药杂志,2014,43(13):1549-1554.
［28］季欣星,徐军建,唐晓.系统评价百令胶囊对糖尿病肾病患者肾功能水平的影响［J］.湖北中医杂志,2014,36(12):3-5.
［29］唐榕,陈路佳,黄玲,等.百令胶囊联合常规治疗早期糖尿病肾病的系统评价［J］.中国药业,2013,22(14):19-23.
［30］李会芳,程生辉,赵换.丹参注射液辅助治疗糖尿病肾病有效性及安全性的系统评价［J］.中国实验方剂学杂志,2013,19(6):353-358.
［31］黄毅岚,杨虹,汪世梅.百令胶囊治疗早期糖尿病肾病的系统评价［J］.中国药业,2012,21(20):18-21.
［32］张煜敏,杨丽萍,沈波.金水宝胶囊治疗糖尿病肾病的系统评价［J］.现代中西医结合杂志,2012,21(23)：2509-2512.
［33］毛家玺,程铭,汤晓静.金水宝治疗糖尿病肾病的系统评价［J］.中国中西医结合肾病志,2012,13(6):526-530.
［34］贺小华,葛振远.百令胶囊防治糖尿病肾病疗效观察的Meta分析［J］.临床荟萃,2012,27(13):1164-1166.
［35］龙轩,王锋,黄昶荃.通心络胶囊治疗糖尿病肾病的系统评价［J］.中国循证医学杂志,2010,10(1):73-80.
［36］王锋,吴红梅.血脂康治疗糖尿病肾病的系统评价［J］.中国循证医学杂志,2009,9(1):63-70.

相似文献/References:

[1]耿翠翠 孙立哲 张杨 李磊强 刘宝刚 王希胜.养正消积胶囊改善宫颈癌术后放化疗骨髓抑制 ５５例[J].陕西中医药大学学报,2018,(05):096.[doi:DOI:10．13424/j．cnki．jsctcm．2018．05．030]
[2]方邦江齐文升任毅 周爽 陈晓蓉 曹敏邓跃毅郭建文 刘力7 刘婉嫣8廖成荣9李旭成0 石李 孙鼎宋娟9 叶勇 杨志旭 尹琴 伍宏泽 郑偕扣 郑月娟张文 张硕 张翔宇7.新冠肺炎奥密克戎变异株中成药应用专家共识[J].陕西中医药大学学报,2022,(06):001.[doi:10.13424/j.cnki.jsctcm.2022.06.001]

备注/Memo

备注/Memo:
基金项目：陕西省自然科学基础研究计划项目（2022JM-494）;陕西省中医药管理局科研计划项目（2019-GJ-QT002）
更新日期/Last Update: 2024-09-09